

REMARKS

Claims 7-8 are pending herein and stand rejected under 35 U.S.C. § 103. Applicants respectfully request reconsideration of the application, withdrawal of all rejections, and allowance of the application in view of the amendments and remarks below.

The Amendments to the Claims

Without prejudice to the Applicants' rights to present claims of equal scope in a timely filed continuing application, to expedite prosecution and issuance of the application, the Applicants have amended claims 7 and 8, and added new claims 9 and 10. The new claims and the amended claims are supported by the specification. The new claims and the amendments to the claims do not introduce new matter. The Examiner is respectfully requested to enter the amendments to the claims and allow all claims.

Rejection under 35 U.S.C. § 103(a)

The Examiner has rejected Claims 7 and 8 under 35 U.S.C. 103(a) as being unpatentable over Gold *et al.* (U.S. 5,270,163) in view of Tullis (WO 88/09810) and Ferns *et al.* (Science 1991, vol. 253, pages 1129-1132). The Examiner proffers that Gold *et al.* teach a method for identifying nucleic acid ligands by a process of *in vitro* selection and amplification; that Tullis teaches nucleic acid conjugates comprising an antisense conjugated to a solubility modifying moiety that may be hydrophobic; and that Ferns *et al.* teach that inhibition of PDGF is a possible approach for prevention of restenosis following angioplasty. Office Action at 3.

By the foregoing amendments, claims 7 and 8 have been amended to recite that the PDGF Nucleic Acid Ligand comprises the sequence ID Number 146. Applicants respectfully submit that this specific PDGF Nucleic Acid Ligand was not taught or suggested, and could not have been reasonably predicted by the cited prior art. As such, Applicants assert that the prior art does not establish *prima facie* obviousness of the claimed invention, and withdrawal of the Section 103 rejections is respectfully requested.

Closing Remarks

Applicants believe the claims are in condition for allowance. If it would be helpful to obtain favorable consideration of this case, the Examiner is encouraged to call and discuss this case with the undersigned.

This constitutes a request for any needed extension of time and an authorization to charge all fees therefore to deposit account No. 19-5117 if not otherwise specifically requested. The undersigned hereby authorizes the charge of any fees created by the filing of this document or any deficiency of fees submitted herewith to be charged to deposit account No. 19-5117.

Respectfully submitted,

Date: September 3, 2008

/Katherine Lobel-Rice/
Katherine Lobel-Rice, #58,079
Swanson & Bratschun, L.L.C.
8210 SouthPark Terrace
Littleton, Colorado 80120
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

S:\ClientFolders\Gilead (formerly NeXstar)\Nex66\D2\NEX 66 D2 Response to Final.doc